A Phase III, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of V212 in Adults with Solid Tumor or Hematologic Malignancy
The purpose of this study is to test the safety and tolerability of the study vaccine, V212 in prevention of shingles in subjects with solid tumor malignancy or hematologic malignancy. In addition this study will evaluate the effectiveness of the study vaccine, V212, as compared to placebo (look-alike vaccine with no active ingredients) in the prevention of shingles in subjects with solid tumor malignancy or hematologic malignancy. The study vaccine (V212) is a varicella-zoster virus (VZV) vaccine that has been treated with a low dose of radiation to kill the virus, producing a non-live virus vaccine.
Back to Clinical Trials list